SGK1 is an AGC kinase that regulates the expression of membrane sodium channels in renal tubular cells in a manner dependent on the metabolic checkpoint kinase complex mTORC2. We hypothesized that SGK1 might represent an additional mTORC2dependent regulator of the differentiation and function of T cells. Here we found that after activation by mTORC2, SGK1 promoted T helper type 2 (T H 2) differentiation by negatively regulating degradation of the transcription factor JunB mediated by the E3 ligase Nedd4-2. Simultaneously, SGK1 repressed the production of interferon-g (IFN-g) by controlling expression of the long isoform of the transcription factor TCF-1. Consistent with those findings, mice with selective deletion of SGK1 in T cells were resistant to experimentally induced asthma, generated substantial IFN-g in response to viral infection and more readily rejected tumors.
AGC kinases are serine-threonine kinases that are broadly involved in regulating various aspects of cell physiology, including growth, survival and metabolism 1 . SGK1 ('serum-and glucocorticoid-regulated kinase 1') is an AGC kinase that is activated by sequential phosphorylation of two highly conserved regulatory motifs: the T-loop domain is phosphorylated at Thr256 by the kinase PDK1 (ref. 2) , and the hydrophobic motif is phosphorylated at Ser422 by the metabolic checkpoint kinase complex mTORC2 (refs. 3,4) . Compared with other AGC kinases that are also downstream of mTOR, such as Akt and S6 kinase, relatively little is known about SGK1. Downstream targets of SGK1 include E3 ubiquitin ligases such as 6) , transcription factors such as Foxo 7, 8 and other kinases such as GSK-3β 9 . In the kidney, SGK1 phosphorylates and inhibits Nedd4-2 to prevent degradation of the epithelial sodium channel and thus allows sodium to be reclaimed in the urine when serum concentrations of sodium are low 5, 10, 11 . It has been shown that SGK1 mRNA is upregulated by sodium in lymphocytes and that mice fed a high-salt diet develop more severe autoimmune encephalomyelitis mediated by the T H 17 subset of helper T cells 12, 13 . Loss of SGK1 in T cells leads to a selective defect in pathogenic T H 17 differentiation due to decreased expression of the receptor for interleukin 23 (IL-23) 12 . The role of SGK1 in other T cell lineages, however, is yet to be determined.
We became interested in SGK1 because it is a downstream target of mTOR, which serves as a critical node in a highly conserved signaling pathway that integrates multiple inputs from the environment 14, 15 . In the immune system, mTOR integrates various signals, such as cytokines and costimulatory molecules, to influence T cell differentiation 15 . mTOR can associate with two distinct protein complexes (mTORC1 and mTORC2) to drive the selective differentiation of CD4 + T cells. Deletion of the gene encoding mTOR in CD4 + T cells has shown that loss of signaling via both mTORC1 and mTORC2 results in differentiation toward a 'default' regulatory T cell phenotype upon activation of T cells 16, 17 . Loss of either mTORC1 or mTORC2 leads to selective deficits in distinct T cell lineages. For example, deletion of the gene encoding the mTORC2 adaptor Rictor in CD4 + T cells results in defective T helper type 2 (T H 2) differentiation characterized by an inability to produce 19) . Despite the critical role of mTOR in regulating the differentiation of effector T cells and regulatory T cells, the precise downstream targets of mTOR that control differentiation into distinct helper T cell subsets have yet to be elucidated.
Because SGK1 is a downstream target of mTORC2, we hypothesized that it might be involved in regulating commitment to the T H 2 lineage by mTORC2. To investigate this, we crossed mice with loxP-flanked alleles encoding (Sgk1 fl/fl ) 11 with mice expressing Cre recombinase from the Cd4 promoter to generate 'T-Sgk1 −/− ' progeny in which SGK1 was selectively deleted in T cells. We found that loss of SGK1 led to less production of IL-4 and inappropriate release of interferon-γ (IFN-γ) under T H 2-polarizing conditions in vitro. In a mouse model of allergic asthma, we found that loss of SGK1 resulted in diminished T H 2 responses and protection against disease. Mechanistically, we found that SGK1 promoted T H 2 differentiation by preventing ubiquitination and degradation of the transcription factor JunB by Nedd4-2 and its adaptor Ndfip. Alternatively, we found that T-Sgk1 −/− mice produced more IFN-γ under T H 1-polarizing conditions in vivo A r t i c l e s than did wild-type mice, and this was associated with stronger antitumor and antiviral immune responses. The ability of SGK1 to inhibit T H 1 differentiation was mediated in part by its ability to regulate expression of the long isoform of the transcription factor TCF-1 via β-catenin and GSK-3β. Overall, our findings define distinct signaling pathways downstream of SGK1 that provide new evidence about how mTOR controls helper T cell differentiation. Fig. 1a ). We wanted to determine whether SGK1 was activated upon stimulation of T cells by measuring phosphorylation of the SGK1 substrate NDRG1 ('N-myc-downregulated gene 1') at Thr346 (ref. 20) . Activation of T cells led to an increase in SGK1 activity (Fig. 1a) . The kinetics of SGK1 activation paralleled those of the mTORC2-dependent activation of Akt (phosphorylation of Akt at Ser473) ( Fig. 1a) .
RESULTS

Activation of SGK1 after recognition of antigen in T cells SGK1 RNA was expressed in resting naive T cells (Supplementary
Next we investigated whether SGK1 activity was modulated by polarizing cytokines upon T cell activation. Consistent with a published report 12 , SGK1 mRNA was expressed under all polarizing conditions in vitro, but its expression was highest under T H 17-polarizing conditions ( Supplementary Fig. 1b) . Notably, we found that SGK1 activity was induced to a similar degree under all polarizing conditions ( Fig. 1b) .
Given the role of mTOR in regulating SGK1 activity in HEK293T human embryonic kidney cells, MCF-7 human breast cancer cells and HeLa human cervical cancer cells 3, 21 , we sought to determine whether SGK1 was also activated in an mTOR-dependent manner in T cells (Supplementary Fig. 2a ). Phosphorylation of NDRG1 increased after T cells were stimulated, but that effect was abrogated in the presence of PP242, an inhibitor of the kinase activity of mTOR 22 (Fig. 1c) . Consistent with those results, we also observed inhibition of the phosphorylation of Akt at Ser473 (Fig. 1c) , which indicated successful blockade of mTORC2 activity [23] [24] [25] . Likewise, T cellspecific deletion of the mTORC2 component Rictor through deletion of loxP-flanked Rictor alleles by Cd4 promoter-driven Cre (T-Rictor -/-) abrogated the activation of both Akt and SGK1 ( Fig. 2a and Supplementary Fig. 2b,c) .
Having established that signaling via SGK1 was dependent on mTORC2 in T cells, we wanted to determine if SGK1 might function downstream of mTORC2 to regulate the differentiation of helper T cells. To address this issue, we bred Sgk1 fl/fl mice 11 with mice with Cd4 promoter-driven Cre expression to generate 'T-Sgk1 −/− ' progeny with selective deletion of SGK1 in T cells (Supplementary Fig. 1a ). After stimulation, phosphorylation of NDRG1 was much lower in T-Sgk1 −/− CD4 + T cells than in their wild-type counterparts ( Fig. 2a) . In contrast, selective deletion of SGK1 in T cells did not affect the phosphorylation of Akt or S6 ( Fig. 2a and Supplementary Fig. 2b,c) .
The role of SGK1 in the maturation of peripheral T cells has not been identified, to our knowledge. Thymic development was essentially not different in wild-type mice versus T-Sgk1 −/− mice ( Supplementary  Fig. 3a) , and there were no differences between wild-type and T-Sgk1 −/− mice in the frequency of B220 + , CD3 + , CD4 + or CD8 + cells in the spleen and lymph nodes ( Fig. 2b-e ). We observed subtle differences between wild-type and T-Sgk1 −/− mice in the absolute number of T cells and expression of activation markers ( Supplementary  Fig. 3b-g) . Finally, the spleens of T-Sgk1 −/− mice had a slightly greater abundance of Foxp3 + T cells (7.50%) than did those of wild-type mice (6.23%); however, we did not observe this difference in the lymph nodes ( Supplementary Fig. 3h) . T-Sgk1 −/− CD4 + T cells displayed a slightly lower rate of proliferation than that of wild-type CD4 + T cells ( Fig. 2f) . Nevertheless, wild-type and T-Sgk1 −/− CD4 + T cells produced similar amounts of IL-2 ( Fig. 2g) . Thus, the lack of SGK1 did not have a substantial effect on the composition of the peripheral T cell compartment.
SGK1 regulates T H 1 and T H 2 differentiation
Given the ability of mTORC2 to regulate the generation of T H 2 cells 18, 19 , we wanted to determine whether loss of SGK1 affected T H 1 and T H 2 differentiation. For this, we obtained CD4 + T cells from wildtype and T-Sgk1 −/− mice, cultured the cells under nonpolarizing (T H 0) or T H 1-or T H 2-polarizing conditions and assessed IL-4 production. As expected, wild-type T cells stimulated under T H 2-polarizing conditions and rechallenged with anti-CD3 and anti-CD28 produced IL-4 ( Fig. 3a) . However, T-Sgk1 −/− T cells did not produce substantial amounts of IL-4 under the same conditions ( Fig. 3a) . Furthermore, lack of SGK1 resulted in lower production of the T H 2 cytokines IL-5 and IL-13 ( Fig. 3b,c) .
Next we assessed the ability of T-Sgk1 −/− T cells to produce IFN-γ and to be polarized into T H 1 effector cells. Without any polarizing cytokines, T cells from C57BL/6 mice 'preferentially' differentiated into T H 1 cells ( Fig. 3d) . Activation of wild-type and T-Sgk1 −/− mice CD4 + T cells cultured under T H 0 or T H 1-polarizing conditions led to the generation of IFN-γ-producing cells ( Fig. 3d) . However, T-Sgk1 −/− T cells had substantial IFN-γ expression even when they were differentiated under T H 2-polarizing conditions ( Fig. 3d) . Thus, T cells that lacked SGK1 did not produce IL-4, IL-5 or IL-13 but instead inappropriately produced IFN-γ under T H 2-polarizing conditions. Consistent with published studies 12, 13 , loss of SGK1 did not affect T H 17 polarization ( Supplementary Fig. 4 ).
Next we investigated the lineage-specific transcription factors T-bet and GATA-3. As expected, wild-type T cells cultured under T H 1-polarizing conditions had abundant expression of T-bet, while wild-type cells cultured under T H 2-polarizing conditions had substantial expression of GATA-3 ( Fig. 3e) (a) Immunoblot analysis of NDRG1 phosphorylated at Thr346 (p-NDRG1(T346)) (SGK1 activity) and Akt phosphorylated at Ser473 (p-Akt(S473)) (mTORC2 activity) in lysates of naive lymphocytes obtained from 5C.C7 mice and allowed to 'rest' for 1 h before stimulation for 0, 1 or 3 h (above lanes) with antibody to CD3 (anti-CD3) and anti-CD28 (TCR + costim); total protein (NDRG1 and Akt) and actin serve as loading controls (throughout). We next investigated the ability of SGK1 to regulate Nedd4-2 in vivo. For this, we adoptively transferred congenically marked (Thy-1.1 + ) ovalbumin (OVA)-specific (OT-II) CD4 + T cells from wild-type or T-Sgk1 −/− mice into naive hosts that we subsequently immunized with OVA adsorbed onto alum to induce a T H 2 response. Similar to the results obtained in vitro, we observed phosphorylation of Nedd4-2 at Ser342 (and thus inhibition of Nedd4-2) after stimulation of wildtype adoptively transferred cells with the OVA epitope (amino acids 329-337) recognized by major histocompatibility complex class II ( Fig. 4b) . In contrast, Nedd4-2 was not phosphorylated nor inhibited in adoptively transferred T-Sgk1 −/− cells.
. In contrast, T-Sgk1 −/− T cells had abundant expression of T-bet when cultured under either
Our data were consistent with the hypothesis that Nedd4-2 degraded JunB protein in T cells lacking SGK1 even under T H 2-polarizing conditions, both in vitro and in vivo. To further test our hypothesis, we activated wild-type and T-Sgk1 −/− CD4 + T cells under T H 2-polarizing conditions in the presence of the proteasome inhibitor MG132. T cells lacking SGK1 had a much lower abundance of JunB than did wild-type T cells ( Fig. 4c) . However, the expression of JunB protein was restored in T-Sgk1 −/− cells in the presence of MG132 ( Fig. 4c) , which suggested that JunB was expressed in T-Sgk1 −/− T cells but was subsequently degraded. To confirm that the degradation of JunB was due to increased ubiquitination, we immunoprecipitated JunB from wild-type and T-Sgk1 −/− CD4 + T cells, followed by immunoblot analysis of ubiquitin. We found that JunB was not ubiquitinated under T H 2-polarizing conditions in wild-type cells, but ubiquitination of JunB was markedly enhanced in the absence of SGK1 ( Fig. 4d ).
Next we sought to determine whether we could restore the ability of T-Sgk1 −/− CD4 + T cells to make IL-4 under T H 2-polarizing conditions by knocking down Nedd4-2 or Ndfip through the use of small interfering RNA (siRNA). Knocking down either Nedd4-2 or Ndfip led to partial restoration of the production of IL-4 in T H 2-polarized T-Sgk1 −/− T cells ( Fig. 4e) . We confirmed the knockdown by measuring the expression of Nedd4-2 mRNA and Ndfip mRNA (Supplementary T H 1-polarizing conditions or T H 2-polarizing conditions. Such cells also failed to express GATA-3 under T H 2-polarizing conditions. Overall, these observations demonstrated a role for SGK1 in reciprocally regulating T H 1 differentiation and T H 2 differentiation. During the differentiation of CD4 + effector T cells, SGK1 activation simultaneously enhanced IL-4 production and inhibited IFN-γ production.
SGK1 regulates T H 2 differentiation by stabilizing JunB
We sought to define the biochemical mechanism by which SGK1 regulated T H 1 and T H 2 differentiation. We did not observe a defect in expression of the receptor for IL-4 or IL-4-induced phosphorylation of STAT6 in the absence of SGK1 (data not shown). Published studies of the role of SGK1 in renal epithelial cells have demonstrated that SGK1 negatively regulates the E3 ligase Nedd4-2 by phosphorylation at Ser342 and Ser448 (refs. 5,10). A closely related homolog of Nedd4-2 is the ubiquitin ligase Itch, which has been shown to interact with the adaptor Ndfip1 ('Nedd4 family-interacting protein 1') to mediate polyubiquitination of JunB 26, 27 . JunB has been shown to be essential for the development of T H 2 cells 26, 28 . We sought to determine if the defect in T H 2 differentiation that we observed in T-Sgk1 −/− mice could have been due in part to increased ubiquitination and degradation of JunB by Nedd4-2. As shown before 28 , the abundance of JunB was higher in wild-type T cells cultured under T H 2-polarizing conditions than in those cultured under T H 1-polarizing conditions (Fig. 4a) . In SGK1-deficient T cells, we observed that the abundance of JunB protein was decreased under both T H 1-polarizing conditions and T H 2-polarizing conditions ( Fig. 4a) . Those findings correlated with the phosphorylation status of Nedd4-2 at Ser342. That is, inhibition of Nedd4-2 (as measured by the phosphorylation of Nedd4-2 at Ser342) was greatest under T H 2-polarizing conditions and was lower in the absence of SGK1 (Fig. 4a ).
npg
A r t i c l e s would be resistant to allergic asthma. Wild-type mice mounted a stereotypical T H 2 response to that allergic stimulus, characterized by IL-4 in bronchoalveolar lavage (BAL) fluid and immunoglobulin E (IgE) in serum ( Supplementary Fig. 6a,b) . However, BAL fluid and serum from T-Sgk1 −/− mice contained significantly less IL-4 and IgE ( Supplementary Fig. 6a,b) . In contrast, we detected OVA-specific IgG2a, characteristic of a T H 1 response, in the serum of T-Sgk1 −/− mice (Supplementary Fig. 6c ). Along those lines, lung lymphocytes from T-Sgk1 −/− mice inappropriately produced IFN-γ when stimulated ex vivo (Supplementary Fig. 6d ). Thus, in this in vivo model of T H 2 cell-mediated inflammation, loss of SGK1 in T cells abrogated the T H 2 response and instead resulted in an inappropriate T H 1 response to an allergic stimulus. Given those findings, we sought to determine if deletion of SGK1 in T cells would prevent allergen-induced lung pathology. For this, Fig. 5a,b) . Additionally, we confirmed knockdown of Nedd4-2 at the protein level, which correlated with the reaccumulation of JunB protein (Fig. 4f) . It was difficult to confirm knockdown of Ndfip at the protein level because the antibodies available lack sensitivity and specificity; however, knockdown of Ndfip also resulted in the reaccumulation of JunB protein (data not shown). Together these results suggested that activation of SGK1 promoted T H 2 differentiation in part by negatively regulating E3 ligases that target JunB for degradation.
Resistance of T-Sgk1 −/− mice to T H 2 cell-mediated asthma
Since we had defined the role of SGK1 in regulating the differentiation of helper T cells in vitro, we wanted to confirm that paradigm in an in vivo model. We chose to study the OVA-alum model of allergic asthma because T H 2 cells are involved in the early pathogenesis of this disease 29 and we therefore hypothesized that T-Sgk1 −/− mice npg we challenged wild-type and T-Sgk1 −/− mice with house dust mite (HDM) extract. Similar to our findings obtained with the OVAalum adjuvant model, we observed a much lower T H 2 response in T-Sgk1 −/− mice than in wild-type mice after challenge with HDM extract (Fig. 5) . Expression of IL-4, IL-13 and IL-5 in the lungs of T-Sgk1 −/− mice was much lower than that in the lungs of wild-type mice (Fig. 5a-c) . Likewise, we observed lower expression of those cytokines by CD4 + T cells in mediastinal lymph nodes from T-Sgk1 −/− mice than in their wild-type counterparts ( Fig. 5d-g) . We observed a much lower absolute number of CD4 + T cells in lymph nodes from T-Sgk1 −/− mice than in their wild-type counterparts; however, there was no significant difference between wild-type and T-Sgk1 −/− mice in this parameter in the lungs or BAL fluid (Supplementary Fig. 6e,f) . Consistent with our model, CD4 + T cells from the lungs, BAL fluid and lymph nodes of T-Sgk1 −/− mice produced significantly more IFN-γ than did those from wild-type mice (Fig. 5h,i) . Furthermore, the T-Sgk1 −/− mice produced less total IgE, in addition to less HDMspecific IgE and IgG1, than did wild-type mice (Fig. 5j-l) . Finally, the lungs of T-Sgk1 −/− mice demonstrated much less goblet-cell hyperplasia and less peribronchiolar and perivascular inflammation than did the lungs of wild-type mice (Fig. 5m-q) . Thus, loss of SGK1 in T cells protected against allergen-induced, T H 2 cell-mediated lung disease.
SGK1 negatively regulates IFN-g production via TCF-1
Disruption of the SGK1-Nedd4-2-Ndfip-JunB axis suggests a possible mechanism for the failure of T-Sgk1 −/− CD4 + T cells to differentiate toward a T H 2 phenotype. However, it does not adequately explain the production of IFN-γ by CD4 + T cells under T H 2 conditions in the absence of SGK1. It has been reported that the kinase GSK-3β is inhibited by the AGC kinases SGK1 and Akt 9 . In turn, GSK-3β phosphorylates β-catenin and targets it for degradation 30, 31 . We observed much lower expression of β-catenin in T-Sgk1 −/− T cells than in wild-type T cells (Fig. 6a) . β-catenin is critical during T H 2 differentiation because it promotes early GATA-3 expression by binding to the proximal promoter of the gene encoding this transcription factor 32 . In the absence of SGK1, GSK-3β remained highly active and thus there was very little total β-catenin (Fig. 6a) . In contrast, npg A r t i c l e s inhibiting GSK-3β in T-Sgk1 −/− T cells with LiCl led to an increase in total β-catenin relative to that obtained with no treatment (Fig. 6a) .
The transcription factor TCF-1 is both a downstream target of β-catenin and a transcriptional coactivator with β-catenin [31] [32] [33] . Similar to T-Sgk1 −/− mice, mice deficient in TCF-1 produce more IFN-γ than do wild-type mice, even under T H 2-polarizing conditions 32 . Specifically, the long isoforms of TCF-1 contain an additional β-catenin-binding domain, and those long isoforms promote T H 2 polarization by increasing GATA-3 expression and repressing IFN-γ expression 32 . We hypothesized that T cells lacking SGK1 would have lower expression of the long form of TCF-1 than would their wild-type counterparts. We cultured wild-type and T-Sgk1 −/− CD4 + T cells under T H 1-or T H 2-polarizing conditions and analyzed their TCF-1 protein. We found that T-Sgk1 −/− cells had a lower abundance of the long isoforms of TCF-1 than did their wild-type counterparts under each condition, but there was no difference between T-Sgk1 −/− cells and wild-type cells in their expression of the short isoforms of TCF-1 (Fig. 6b) .
To determine if SGK1 regulates TCF-1 expression at the transcriptional level, we designed primers that flank the β-catenin-binding domain to specifically detect the long isoform of TCF-1. We observed less transcription of the long isoforms of TCF-1 at 72 h after activation of the T cell antigen receptor in SGK1-deficient cells than in wildtype cells and observed a complete absence of transcripts at 8 d after such stimulation (Fig. 6c) . To further test our hypothesis, we sought to 'rescue' the phenotype of T-Sgk1 −/− CD4 + T cells by retroviral transduction with a vector encoding the long isoform of TCF-1 and a human monomorphic coreceptor CD8 reporter. We sorted transduced cells for expression of human CD8, then restimulated the cells with anti-CD3 and anti-CD28 and measured the production of IFN-γ by intracellular staining. Wild-type T cells cultured under T H 2-polarizing conditions did not express IFN-γ (Fig. 6d) . T-Sgk1 −/− T cells transduced with the empty vector had substantial expression of IFN-γ under T H 2-polarizing conditions (Fig. 6d) . In contrast, IFN-γ expression was diminished in T-Sgk1 −/− T cells transfected with vector encoding the long isoform of TCF-1 and the reporter (Fig. 6d) .
These data supported a model whereby under T H 2-polarizing conditions, SGK1 inhibited the GSK-3β-mediated degradation of β-catenin, which led in turn to higher expression of the long form of TCF-1 and inhibition of IFN-γ (Supplementary Fig. 7) .
T-Sgk1 −/− mice mount robust T H 1 cell-mediated immune responses
The ability of SGK1 to regulate T H 2 responses is due in part to its ability to negatively regulate IFN-γ. We sought to determine whether T-Sgk1 −/− mice would also produce more IFN-γ in vivo under strongly T H 1-polarizing conditions. For this, we adoptively transferred congenically marked Thy-1.1 + , OVA-specific wild-type and T-Sgk1 −/− CD4 + T cells into Thy-1.2 + wild-type mice that we simultaneously infected intravenously with OVA-expressing vaccinia virus, which induces robust T H 1 immune responses. Infection with that virus led to a greater abundance of OVA-specific, IFN-γ-producing cells in T-Sgk1 -/mice than in wild-type mice (Fig. 7a) . In addition, the T H 1 response in T-Sgk1 −/− mice was characterized by a greater amount of IFN-γ produced (on a per-cell basis) than that produced by their wild-type counterparts (Fig. 7a) . To confirm those observations, we challenged wild-type and T-Sgk1 −/− mice with the PR8 strain of influenza virus, which also promotes a strong T H 1-mediated immune response. Similar to the results we obtained with vaccinia virus, in response to infection with influenza virus, CD4 + T cells from T-Sgk1 −/− mice produced more IFN-γ than did their wild-type counterparts (Fig. 7b) .
To further assess the T H 1 response of T-Sgk1 −/− cells in vivo, we used a model of T H 1 cell-mediated tumor rejection, since T H 1-polarized CD4 + T cells have been shown to serve an important role in antitumor immunity 34 . To address that, we injected 2 × 10 5 B16 mouse melanoma cells intravenously into wild-type and T-Sgk1 −/− mice and collected their lungs 21 d later. T-Sgk1 −/− mice had less than half as many lung tumors as wild-type mice had ( Fig. 7c and Supplementary  Fig. 8) . While it is possible that the lower tumor burden could have been promoted by CD8 + T cells, it was apparent that the more effective response of the T-Sgk1 −/− mice was associated with a greater npg abundance of IFN-γ-producing CD4 + T cells in the lungs (Fig. 7d) .
Next we sought to further boost tumor immunity in T-Sgk1 −/− mice by vaccination. We immunized mice with OVA-expressing vaccinia virus 7 d before intravenously injecting OVA-expressing B16 cells, then monitored survival as the main outcome. We found that T-Sgk1 −/− mice survived significantly longer than did wild-type mice in response to the tumor vaccine ( Fig. 7e) . Thus, targeted deletion of SGK1 in T cells led to enhanced tumor immunity characterized by more production of IFN-γ and robust immunological rejection of tumors.
DISCUSSION
A critical task of the adaptive and innate immune systems is to integrate cues from the immunological microenvironment and then respond appropriately. It has become clear that the evolutionarily conserved serine-threonine kinase mTOR has a central role in this process 15 . The outcome of the activation of mTOR is determined by the regulation of selective downstream signaling pathways and substrates. We have identified the AGC kinase SGK1 as an mTORC2-activated substrate that selectively regulated the differentiation of T H 1 and T H 2 cells. T cells lacking SGK1 demonstrated a markedly diminished ability to differentiate into T H 2 cells both in vitro and in vivo. Furthermore, under T H 2-polarizing conditions, T-Sgk1 −/− T cells inappropriately produced IFN-γ. Thus, under T H 2-polarizing conditions, SGK1 simultaneously promoted T H 2 differentiation while also inhibiting the production of T H 1 cytokines. Likewise, we observed greater IFN-γ production by T-Sgk1 −/− T cells in vivo in the setting of viral infection and antitumor immunity. Of note, under T H 1-polarizing conditions in vitro, T-Sgk1 −/− and wild-type T cells produced equivalent amounts of IFN-γ. Perhaps that indicated that under strongly polarizing conditions in vitro, the ability of SGK1 to inhibit the T H 1 response was inconsequential. However, under in vivo inflammatory conditions that predominantly favored T H 1 polarization, signaling by SGK1 seemed to limit the magnitude of the T H 1 immune response.
Our studies have defined a mechanism by which activation of mTOR (specifically mTORC2) regulated T H 1 and T H 2 differentiation. It has been reported that SGK1 has a role in promoting the stability of pathogenic T H 17 cells 12 . Notably, in that study, as in ours, T H 17 differentiation was similar in both wild-type and T-Sgk1 −/− T cells. However, that study demonstrated a role for SGK1 in controlling expression of the IL-23 receptor 12 . As a result, T cells lacking SGK1 respond poorly to IL-23, and T-Sgk1 −/− mice are resistant to the development of experimental autoimmune encephalitis 12 . Furthermore, an increase in the extracellular concentration of sodium leads to increased IL-23-mediated T H 17 differentiation and that effect is abrogated in T-Sgk1 −/− T cells 12 . The authors of that report 12 and another study 13 attribute their findings to the ability of an increase in dietary salt to exacerbate experimental autoimmune encephalitis.
Published studies of the role of SGK1 in the kidney have provided clues about how this AGC kinase may function in T cells 11 . To allow sodium to be reclaimed in the urine, SGK1 prevents the degradation of sodium channels by phosphorylating and inhibiting the E3 ubiquitin ligase Nedd4-2 (refs. 5,6) . Similarly, we found that SGK1 promoted T H 2 differentiation by phosphorylating and inhibiting Nedd4-2, thus preventing degradation of JunB. Those findings are consistent with studies reporting that mice that lack Ndfip or Itch display a 'hyper-T H 2' phenotype 26, 27 . In those studies, loss of Ndfip or Itch led to the accumulation of JunB and increased expression of IL-4. Overall, our studies serve to strengthen the link between mTOR-SGK1 and the regulation of cellular differentiation and function by E3 ligases. Just as the ability of mTOR to regulate E3 ligase activity has been shown to be important in T cells and renal epithelial cells, we propose that these regulatory pathways will prove to be important for diverse cellular functions.
Our findings have identified SGK1 as a potential target for the treatment of T H 2 cell-mediated autoimmune and allergic diseases, such as asthma. At present, nonspecific immunosuppressive agents such as steroids serve an important role in the treatment of acute asthma flares, as well as in the prevention of recurrences [35] [36] [37] . Our data suggest that selective inhibition of SGK1 might represent an immunomodulatory approach for treating and preventing the sequelae of asthma and other allergic diseases without globally inhibiting the immune system. Notably, small-molecule inhibitors of SGK1 have already been developed 38, 39 . Additionally, inhibiting SGK1 may be of therapeutic value in terms of enhancing T H 1 cell-mediated immune responses, such as in the setting of viral infection or as an adjunct to tumor immunotherapy. Thus, whereas an asthmatic patient might be treated with an inhibitor npg of SGK1 to prevent the development of T H 2 cell-mediated inflammation, the same small-molecule inhibitor might be given to a patient during cancer immunotherapy to enhance the antitumor response.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
